Drug intelligence / Profile preview

AIP 301

Development stage: Unknown
Lead developer: AIP
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AIP 301 is a diagnostic radiopharmaceutical candidate being developed by Advanced Innovative Partners (AIP) for the detection and imaging of breast cancer. As a diagnostic agent, it is designed to bind to specific molecular markers on breast cancer cells, allowing for the visualization of primary tumors and metastatic lesions through nuclear medicine imaging techniques such as PET or SPECT. This approach aims to improve the accuracy of breast cancer diagnosis, staging, and monitoring. AIP 301 is currently in Phase 1 clinical development, representing the diagnostic component of AIP's breast cancer program, which also includes a therapeutic counterpart (AIP 303).

Other names: AIP 301-AIP-radiopharmaceutical-Breast Cancer (Diagnostic)

Beyond the preview

Go deeper on AIP 301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIP 301.

Explore the full profile